BioNexus Gene Lab Corp Common stock (BGLC) - Total Assets
Based on the latest financial reports, BioNexus Gene Lab Corp Common stock (BGLC) holds total assets worth $7.62 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioNexus Gene Lab Corp Common stock - Total Assets Trend (2016–2024)
This chart illustrates how BioNexus Gene Lab Corp Common stock's total assets have evolved over time, based on quarterly financial data. Also see BGLC market cap overview for the company's overall valuation and market capitalisation.
BioNexus Gene Lab Corp Common stock - Asset Composition Analysis
Current Asset Composition (December 2024)
BioNexus Gene Lab Corp Common stock's total assets of $7.62 Million consist of 71.2% current assets and 28.8% non-current assets. Review BGLC current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.0% |
| Accounts Receivable | $1.58 Million | 15.2% |
| Inventory | $1.39 Million | 13.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how BioNexus Gene Lab Corp Common stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See BGLC live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioNexus Gene Lab Corp Common stock's current assets represent 71.2% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 42.0% of total assets in 2024, down from 100.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 15.2% of total assets.
BioNexus Gene Lab Corp Common stock Competitors by Total Assets
Key competitors of BioNexus Gene Lab Corp Common stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP
|
Germany | €16.13 Billion |
|
Zhejiang Longsheng Group Co Ltd
SHG:600352
|
China | CN¥76.50 Billion |
|
LB Group Co Ltd
SHE:002601
|
China | CN¥63.89 Billion |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
China | CN¥6.27 Billion |
|
Qingdao Gon Technology Co Ltd
SHE:002768
|
China | CN¥21.26 Billion |
|
Lianhe Chemical Technology Co Ltd
SHE:002250
|
China | CN¥13.79 Billion |
|
Guangzhou Sanfu New Materials Technology Co. Ltd. A
SHG:688359
|
China | CN¥1.36 Billion |
|
Rianlon Corp
SHE:300596
|
China | CN¥10.69 Billion |
BioNexus Gene Lab Corp Common stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.30 | 4.98 | 2.37 |
| Quick Ratio | 6.81 | 3.99 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.95 Million | $5.62 Million | $4.61 Million |
BioNexus Gene Lab Corp Common stock - Advanced Valuation Insights
This section examines the relationship between BioNexus Gene Lab Corp Common stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.87 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -8.5% |
| Total Assets | $10.43 Million |
| Market Capitalization | $3.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioNexus Gene Lab Corp Common stock's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BioNexus Gene Lab Corp Common stock's assets decreased by 8.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioNexus Gene Lab Corp Common stock (2016–2024)
The table below shows the annual total assets of BioNexus Gene Lab Corp Common stock from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $10.43 Million | -8.47% |
| 2023-12-31 | $11.40 Million | +30.43% |
| 2022-12-31 | $8.74 Million | -8.71% |
| 2021-12-31 | $9.57 Million | -5.35% |
| 2020-12-31 | $10.12 Million | +721.56% |
| 2019-12-31 | $1.23 Million | -25.48% |
| 2018-12-31 | $1.65 Million | +29.80% |
| 2017-12-31 | $1.27 Million | +4895592.31% |
| 2016-12-31 | $26.00 | -- |
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more